XCancer

PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas

Description:

This pilot study aims to investigate the PSMA expression in the biopsy material of advanced soft tissue sarcomas and advanced urothelial cell carcinomas, and in case of high PSMA expression (as defined by previous literature), to investigate whether this correlates with high tracer uptake on PSMA-targeted PET. This way, (a subset of) patients can be selected that could benefit from radionuclide targeted therapy in the future.

Sponsor:

Leiden University Medical Center

Phase:

N/A

Contacts:

Lioe-Fee De Geus-Oei, prof.dr. (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT05522257 - Click here to see study on

ClinicalTrials.gov

JK-PSMA-7

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Inclusion
  • * Age \>/= 18 years at the time of informed consent.
  • Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.
  • Diagnosis of advanced (locally irresectable or metastasized) soft tissue sarcoma (cohort 1) or advanced (muscle invasive or metastasized) urothelial cell carcinoma (cohort 2).
  • Biopsy available of primary tumour and/or metastasis
  • Recent (\< 8 weeks) standard imaging (with CT or \[18F\]-FDG PET/CT) with measurable disease (lesion diameter \> 1 cm).
Exclusion
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
  • Inability to undergo PET/CT scanning, e.g. claustrophobia, weight limits or inability to tolerate lying down for the duration of a PET/CT scan (\~30 minutes).
  • * Women who are pregnant and/or lactating.
  • Known hypersensitivity to drugs comparative to \[18F\]-JK-PSMA-7, any of their excipients or to any component of \[18F\]-JK-PSMA-7.